Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms
Open Access
- 20 January 2016
- journal article
- other
- Published by Taylor & Francis in mAbs
- Vol. 8 (2) , 389-404
Abstract
Transforming growth factor (TGF)β levels are elevated in, and drive the progression of, numerous disease states such as advanced metastatic cancer and systemic and ocular fibrosis. There are 3 main isoforms, TGFβ1, 2, and 3. As multiple TGFβ isoforms are involved in disease processes, maximal therapeutic efficacy may require neutralization of 2 or more of the TGFβ isoforms. Fully human antibody phage display libraries were used to discover a number of antibodies that bind and neutralize various combinations of TGFβ1, 2 or 3. The primary panning did not yield any uniformly potent pan-isoform neutralizing antibodies; therefore, an antibody that displayed potent TGFβ 1, 2 inhibition, but more modest affinity versus TGFβ3, was affinity matured by shuffling with a light chain sub-library and further screening. This process yielded a high affinity pan-isoform neutralizing clone. Antibodies were analyzed and compared by binding affinity, as well as receptor and epitope competition by surface plasmon resonance methods. The antibodies were also shown to neutralize TGFβ effects in vitro in 3 assays: 1) interleukin (IL)-4 induced HT-2 cell proliferation; 2) TGFβ-mediated IL-11 release by A549 cells; and 3) decreasing SMAD2 phosphorylation in Detroit 562 cells. The antibodies’ potency in these in vitro assays correlated well with their isoform-specific affinities. Furthermore, the ability of the affinity-matured clone to decrease tumor burden in a Detroit 562 xenograft study was superior to that of the parent clone. This affinity-matured antibody acts as a very potent inhibitor of all 3 main isoforms of TGFβ and may have utility for therapeutic intervention in human disease.Keywords
This publication has 62 references indexed in Scilit:
- Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patientsOncoImmunology, 2013
- Induction and molecular signature of pathogenic TH17 cellsNature Immunology, 2012
- TGF-β – an excellent servant but a bad masterJournal of Translational Medicine, 2012
- A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosisKidney International, 2011
- Prodomains of Transforming Growth Factor β (TGFβ) Superfamily Members Specify Different FunctionsJournal of Biological Chemistry, 2011
- Targeting the transforming growth factor-β signalling pathway in metastatic cancerEuropean Journal of Cancer, 2010
- A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactionsProceedings of the National Academy of Sciences, 2008
- Transforming Growth Factor-beta (TGF-β) Binding to the Extracellular Domain of the Type II TGF-β Receptor: Receptor Capture on a Biosensor Surface Using a New Coiled-coil Capture System Demonstrates that Avidity Contributes Significantly to High Affinity BindingJournal of Molecular Biology, 2003
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Mechanism of activation of the TGF-β receptorNature, 1994